Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection;Il problema della resistenza ai farmaci antipiastrinici: Meccanismi molecolari e test di laboratorio

Rivista Italiana della Medicina di Laboratorio

Volumn 5, Issue 2, 2009, Pages 119-124

  Pugliano, M ^a   Cattaneo, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Blood platelets; Drug resistance; Platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 1; CYTOCHROME; PRODRUG; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE A2; THROMBOXANE B2;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; DRUG METABOLISM; HUMAN; LABORATORY TEST; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; REVIEW; RISK REDUCTION; THERAPY RESISTANCE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 66849106882     PISSN: 1825859X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Cattaneo M. Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24:1980-1987
2. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287-1294 (Pubitemid 24129964)
3. Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995; 270:10902-10908
4. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schrör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353:900. (Pubitemid 29126885)
5. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, et al. Ciclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002; 99: 7634-7639 (Pubitemid 34568743)
6. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19:2281-2285 (Pubitemid 29477827)
7. Cattaneo M, Lombardi R, Zighetti ML, Gachet C, Ohlman P, Cazenave J-P, et al. Deficiency of [33P]2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxaneA2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Thromb Haemost 1997; 77:986-990
8. Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 2000; 20:E101-6.
9. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nature Rev 2003; 2:15-28. (Pubitemid 37361621)
10. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1:1710-1713
11. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 5(Suppl 1):230-237 (Pubitemid 46958838)
12. Campbell CL, Steinhubl SR. Variability in response to aspirin: do we understand the clinical relevance? J Thromb Haemost 2005; 3:665-669
13. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006; 4:1271-1278 (Pubitemid 43756705)
14. Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a randomized crossover study in 96 healthy volunteers. J Thromb Haemost 2006; 4:813-819
15. Frelinger AL 3rd, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113:2888-2896
16. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46:1705-1709 (Pubitemid 41531626)
17. Williams MS, Kickler TS, Vaidya D, Ng'alla LS, Bush DE. Evaluation of platelet function in aspirin treated patients with CAD. J Thromb Thrombolysis 2006; 21:241-247 (Pubitemid 43676781)
18. Geiger J, Brich J, Honig-Liedl P, Eigenthaler M, Schanzenbacher P, Herbert JM, et al. Specific impairment of human platelet P2Y(AC) receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19:2007-2011. (Pubitemid 29379936)
19. LauWC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DGM, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109:166-171 (Pubitemid 38114134)
20. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247 (Pubitemid 44497506)
21. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clo pidogrel. Arterioscler Thromb Vasc Biol 2006; 26: 1895-1900 (Pubitemid 44305347)
22. Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006; 174:1715-1722 (Pubitemid 43893560)
23. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-375
24. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005; 116:491-497 (Pubitemid 41330814)
25. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360:354-362
26. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48:475-484
27. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32:821-827 (Pubitemid 38955611)
28. Aubert RE, Epstein RS, Teagarden JR, Xia F, Yao J, Desta Z, Skaar T, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study. Circulation 2008; 118:S-815.
29. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180:713-718
30. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301:937-944
31. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51:256-260
32. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80:486-501. (Pubitemid 44767878)
33. Feher G, Koltai K, Alkonyi B, Papp E, Keszthelyi Z, Kesmarky G et al. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol 2007; 120: 188-192 (Pubitemid 47042251)
34. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006; 4:1271-1278 (Pubitemid 43756705)
35. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138:152-163 (Pubitemid 32812228)
36. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4:312-319
37. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2003; 108:37-42.
38. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36:1001-1005 (Pubitemid 40629292)
39. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006; 28:315-322 (Pubitemid 44047198)
40. von Beckerath N, Pogatsa-Murray G, Wieczorek A, Sibbing D, Schomig A, Kastrati A. Correlation of a new pointof- care test with conventional optical aggregometry or the assessment of clopidogrel responsiveness. Thromb Haemost 2006; 95:910-911
41. van Werkum JW, van der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006; 4:2516-2518 (Pubitemid 44575456)
42. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets - definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82:1145-1152 (Pubitemid 29419734)
43. Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005; 51:957-965 (Pubitemid 40740875)
44. Grossmann R, Sokolova O, Schnurr A, Bonz A, Porsche C, Obergfell A, et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92:1201-1206 (Pubitemid 39642526)
45. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3:85-92. (Pubitemid 41647119)
46. Pampuch A, Cerletti C, de Gaetano G. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 2006; 96:767-773 (Pubitemid 44883817)
47. Agarwal S, Coakley M, Reddy K, Riddell A, Mallett S. Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry. Anesthesiology 2006; 105: 676-683 (Pubitemid 44477312)
48. 2 metabolites in humans. Thromb Res 1987; 47:647-656